CORDIS
EU research results

CORDIS

English EN
Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network

Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network

Objective

Breast and ovarian cancer constitute serious health challenges in the EU. To identify new improved cancer therapeutic approaches, we will pursue a multi-facetted synthetic lethal approach, which takes advantage of the inherent genetic instability of cancer cells. Most mutations acquired by cancer cells do not cause lethality, but the very same mutations may cause cell death when a second gene in a redundant pathway is inactivated. Thus, targeting a gene that is synthetic lethal together with a cancer-specific mutation will kill only cancer cells while sparing normal cells. Synthetic lethal approaches have been clinically pioneered by members of our consortium, by combining cancer-promoting mutations (e.g. in BRCA2) with inactivating combinations of DNA repair genes. We will use this approach as the scientific frame for our ETN (SYNTRAIN) consisting of 9 academic and 1 SME beneficiary as well as 3 partners. We aim to identify synthetic lethal interactions and exploit them to innovate future breast and ovarian cancer treatments through compound screening and development. SYNTRAIN consists of World leading researchers with complementary knowledge in genome maintenance and stress response pathways, and a critical mass of expertise for providing an excellent training in screening methodologies, mechanistic investigations, and drug discovery. We will offer a structured training program that exceeds the capacities of each individual member. We will educate a future generation of cancer researchers with a high innovative capacity and skills that enhances their career prospects in both academia and industry. Our aims are to train young researchers: i) in techniques preparing for a career in cancer research, ii) in complementary skills relevant for work in academia and the pharma industry and iii) to become creative and entrepreneurial, capable of bridging the gap between basic and applied research.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KOBENHAVNS UNIVERSITET

Address

Norregade 10
1165 Kobenhavn

Denmark

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 580 163,76

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE

Italy

EU Contribution

€ 258 061,32

PANEPISTIMIO PATRON

Greece

EU Contribution

€ 242 386,92

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 527 318,64

KRAEFTENS BEKAEMPELSE

Denmark

EU Contribution

€ 290 081,88

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 546 575,76

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 265 226,76

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

EU Contribution

€ 510 748,56

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece

EU Contribution

€ 242 386,92

KANCERA AB

Sweden

EU Contribution

€ 527 318,64

Partners (3)

Sort alphabetically

Expand all

MISVIK BIOLOGY OY

MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Project information

Grant agreement ID: 722729

Status

Ongoing project

  • Start date

    1 September 2016

  • End date

    31 August 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 990 269,16

  • EU contribution

    € 3 990 269,16

Coordinated by:

KOBENHAVNS UNIVERSITET

Denmark